Evidence map›Paper›PMID 42279390›Full record

ArticleCancers2026

Safety and Efficacy of Stereotactic Body Radiation Therapy in Very Elderly Patients (≥80 Years) with Solitary Hepatocellular Carcinoma.

Yuki Tamura, Hiroki Tojima, Daichi Takizawa, Mitsuhiko Shibasaki, Hirotaka Arai, Hiroki Kiyohara, Yukihiko Yoshimatsu, Takashi Ueno, Takashi Kosone, Toru Fukuchi and 6 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancers, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Yuki TamuraDepartment of Gastroenterology and Hepatology, Gunma University Graduate School of Medicine, Maebashi 370-0829, Japan.ORCID 0009-0002-8947-2874
Hiroki TojimaDepartment of Gastroenterology and Hepatology, Gunma University Graduate School of Medicine, Maebashi 370-0829, Japan.
Daichi TakizawaDepartment of Gastroenterology, Japanese Red Cross Maebashi Hospital, Maebashi 371-0811, Japan.ORCID 0000-0002-2004-8285
Mitsuhiko ShibasakiDepartment of Gastroenterology, Japanese Red Cross Maebashi Hospital, Maebashi 371-0811, Japan.
Hirotaka AraiDepartment of Gastroenterology, Japanese Red Cross Maebashi Hospital, Maebashi 371-0811, Japan.
Hiroki KiyoharaDepartment of Radiation Oncology, Japanese Red Cross Maebashi Hospital, Maebashi 371-0811, Japan.
Yukihiko YoshimatsuDepartment of Radiation Oncology, Japanese Red Cross Maebashi Hospital, Maebashi 371-0811, Japan.
Takashi UenoDepartment of Internal Medicine, Isesaki Municipal Hospital, Isesaki 372-0817, Japan.
Takashi KosoneDepartment of Gastroenterology and Hepatology, Kusunoki Hospital, Fujioka 375-0024, Japan.
Toru FukuchiDepartment of Internal Medicine, Kiryu Kosei General Hospital, Kiryu 376-0024, Japan.
Takayoshi SugaDepartment of Gastroenterology, NHO Shibukawa Medical Center, Shibukawa 377-0024, Japan.
Shuichi SaitoDepartment of Gastroenterology, Tomioka Public General Hospital, Tomioka 370-2316, Japan.
Hideyuki SuzukiDepartment of Internal Medicine, Japanese Red Cross Haramachi Hospital, Higashiagatsuma 377-0801, Japan.
Yuichi YamazakiDepartment of Gastroenterology and Hepatology, Gunma University Graduate School of Medicine, Maebashi 370-0829, Japan.ORCID 0000-0002-8633-2983
Satoru KakizakiDepartment of Clinical Research, NHO Takasaki General Medical Center, Takasaki 370-0829, Japan.ORCID 0000-0003-0224-7093
Toshio UraokaDepartment of Gastroenterology and Hepatology, Gunma University Graduate School of Medicine, Maebashi 370-0829, Japan.ORCID 0000-0002-4425-4331

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe number of elderly patients with hepatocellular carcinoma (HCC) has been increasing worldwide. This study aimed to evaluate the clinical outcomes of stereotactic body radiation therapy (SBRT) for patients aged ≥80 years with solitary HCC.

methodsThis retrospective study included 117 patients with solitary HCC treated with SBRT between January 2019 and June 2025 at eight institutions in Japan. Patients were categorized into the very elderly group (≥80 years,

resultsThe median age was 84 years in the very elderly group and 74 years in the control group. The 3-year OS rates were 79.0% in the very elderly group and 62.8% in the control group, with no statistically significant difference observed (crude cohort: 95% CI, 0.18-1.08,

conclusionsSBRT may represent a feasible treatment option with an acceptable safety profile in carefully selected very elderly patients with solitary HCC. It may be a reasonable option for this growing patient population.

Indexed as

alternative treatmentclinicalelderly patientshepatocellular carcinomaradiation therapy

Identifiers

PMID42279390
PMCPMC13255915

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.